Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RNS60 in Allergen-induced Bronchoconstriction
NCT02497222Phase 2Withdrawn
- Sponsor
- Revalesio Corporation
- Primary completion
- Jun 2016
- Modality
- Nanoparticles, Small Molecules, Device-based Delivery
- Countries
- 1
01
Overview
A Phase 2 trial of RNS60 in asthma, sponsored by Revalesio Corporation. Status: withdrawn.
02
Drugs
RNS60
03
Conditions
asthma
Beyond the preview
Go deeper on NCT02497222.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02497222.